Protecting bone health for patients receiving Ra-223 + ARPI combination
An expert discusses what has been learned about the use of bone-protecting agents and bone density scans for patients receiving an androgen receptor pathway inhibitor (ARPI) in combination with radium-223, based on data from the Phase 3 PEACE-3 study (Enza + Ra-223) and the Phase 3 ERA-223 study (AAP + Ra-223).
Video Player is loading.
- What has been learned about use of bone protecting agents and bone density scans for patients receiving an ARPI in combination with Ra-223?
- Phase 3 PEACE 3 – Enza + Ra-223
- Phase 3 ERA 223, AAP + Ra-223
Recent Videos
Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches
Advances in MPN Management: Insights From MANIFEST-2 and Beyond
Ongoing studies of Ra-223–based combinations
Academic Perspectives on Systemic Therapy for Advanced uHCC
Considerations for Treatment Approaches in Intermediate-Stage HCC
Navigating the Evolving First-Line Treatment Regimens in Intermediate-Stage HCC
Optimizing Frontline TKI Therapy in Advanced uHCC: Managing Adverse Events
ROS1 Inhibition: AE Management
Treatment Decision-Making for Metastatic NSCLC With a ROS1 Alteration
The Role of CD123 Targeted Therapy (tagraxofusp) in the Evolving Treatment Landscape for BPDCN
Related Content
